Journal of Antimicrobial Chemotherapy

Article	Citations
Correction to: Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomon	104
Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching—authors’ response	87
Low rates of complications and β-lactam resistance in viridans group streptococci bloodstream infection among cancer patients receiving chemotherapy	81
Epidemiology and clinical relevance of persistent bacteraemia in patients with Gram-negative bloodstream infection: a retrospective cohort study	76
Evaluation of the RESIST ACINETO multiplex immunochromatographic assay for detection of OXA-23-like, OXA-40/58-like and NDM carbapenemase production in Acinetobacter baumannii	60
Bictegravir-based antiretroviral therapy in HIV-1 group O patients: data from real-life bictegravir/emtricitabine/tenofovir alafenamide switches	60
Conventional versus extended-pulsed fidaxomicin dosing in patients at high risk of recurrence ofClostridioides difficileinfection: a propensity score analysis	57
Neonatal sepsis due to NDM-1 and VIM-2 co-producing Pseudomonas aeruginosa in Morocco	55
Correlation between rrs gene mutations and amikacin resistance in Mycobacterium abscessus: implications for fitness cost and clinical prevalence	52
Correction to: Phenotypic and genotypic analysis of antimicrobial resistance in Nocardia species	51
Phenotypic and genotypic antimicrobial susceptibility patterns of the emerging human respiratory pathogen Mycoplasma amphoriforme isolated from the UK and Denmark	50
Development and application of Cas13a-based diagnostic assay forNeisseria gonorrhoeaedetection and azithromycin resistance identification	49
A novel Bacteroides metallo-β-lactamase (MBL) and its gene (crxA) in Bacteroides xylanisolvens revealed by genomic sequencing and functional analysis	49
Genomic analyses of Staphylococcus aureus isolated from yaks in Ganzi Tibetan Autonomous Prefecture, China	49
Emergence of the mobile RND-type efflux pump gene cluster tmexCD1-toprJ1 in Klebsiella pneumoniae clinical isolates in Japan	45
Distinct molecular epidemiology of resistances to extended-spectrum cephalosporins and carbapenems in Enterobacter hormaechei in cats and dogs versus horses in France	45
General practice antibiotic prescriptions attributable to respiratory syncytial virus by age and antibiotic class: an ecological analysis of the English population	45
Transmission barrier of the blaKPC plasmid mediated by type I restriction-modification systems in Escherichia coli	44
Off-label use of dalbavancin in children: a case series	43
Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics	42
Genomic and transcriptomic variation in Bordetella spp. following induction of erythromycin resistance	42
Prosthetic joint infections: 6 weeks of oral antibiotics results in a low failure rate	41
Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection	40
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study	40
Engineering a CRISPR interference system targeting AcrAB-TolC efflux pump to prevent multidrug resistance development in Escherichia coli	40

Mitigation of benznidazole toxicity and oxidative stress following ascorbic acid supplementation in an adult traveller with chronic indeterminate Chagas’ disease	39
Fatal invasive pulmonary and cerebral aspergillosis due to triazole-resistant Aspergillus fumigatus with multiple CYP51A mutations	39
Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus	38
Simultaneous pharmacokinetic/pharmacodynamic (PKPD) assessment of ampicillin and gentamicin in the treatment of neonatal sepsis	38
SQ31f is a potent non-tuberculous mycobacteria antibiotic by specifically targeting the mycobacterial F-ATP synthase	37
Pharmacokinetics and pharmacogenetics of high-dosage tedizolid for disseminated nocardiosis in a lung transplant patient	35
Specific mutations in the HIV-1 G-tract of the 3′-polypurine tract cause resistance to integrase strand transfer inhibitors	35
Liposomal amikacin and Mycobacterium abscessus: intimate interactions inside eukaryotic cells	35
Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus	34
Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis	33
Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads	32
Point-of-care tests to manage acute respiratory tract infections in primary care: a systematic review and qualitative synthesis of healthcare professional and patient views	32
Establishment of epidemiological cut-off values of etimicin: a new fourth-generation aminoglycoside, against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudom	32
The impact of palliative care consultation on reducing antibiotic overuse in hospitalized patients with terminal cancer at the end of life: a propensity score-weighting study	32
Uropathogenic Escherichia coli population structure and antimicrobial susceptibility in Norfolk, UK	32
Comment on: A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections	31
Ultra-rapid selection of the N74D capsid inhibitor resistance mutation after 3 weeks on lenacapavir	31
Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions	31
NDM-5-producing Klebsiella pneumoniae ST258 in a university hospital in Argentina	31
Liver cyst penetration of antibiotics at the target site of infection: a randomized pharmacokinetic trial	30
Correction to: Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV	30
Systematic review on oral antibacterial relay therapy for acute staphylococcal prosthetic joint infections treated with debridement, antibiotics and implant retention (DAIR)	30
Effect of empiric antibiotics against Pseudomonas aeruginosa on mortality in hospitalized patients: a systematic review and meta-analysis—authors’ response	29
Oral antimicrobial agents in patients with short bowel syndrome: worth a try!—authors’ response	29
Plasma concentration of orally administered amoxicillin and clindamycin in patients receiving haemodialysis	29
Antibiotic biocompatibility assay and anti-biofilm strategies for Pseudomonas aeruginosa infection in bioengineered artificial skin substitutes	29
Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children	29
Plasmodium falciparum isolates: ex vivo drug response	28
Antibiotic-induced degradation of antitoxin enhances the transcription of acetyltransferase-type toxin-antitoxin operon	27
In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium	27
Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions	27
Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort	27
Activity of fosfomycin/colistin combinations against planktonic and biofilm Gram-negative pathogens	26
Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin/tazobactam and carbapenems: a mul	26
In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model	26
Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions?	26
Activity of mecillinam against carbapenem-resistant Enterobacterales	26
Current practices and challenges of outpatient parenteral antimicrobial therapy: a narrative review	25
Synergistic effects of quorum-sensing molecules and antimicrobials against Candida albicans and Pseudomonas aeruginosa biofilms: in vitro and in vivo studies	25
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae	24
Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre inf	24
Genomic analysis reveals the population structure and antimicrobial resistance of avian Pasteurella multocida in China	24
Comment on: Community-acquired pneumonia: a US perspective on the guideline gap	24
Characterization of a multiresistance optrA- and lsa(E)-harbouring unconventional circularizable structure in Streptococcus suis	24
Leveraging interdisciplinary management in people with HIV and lymphoid neoplasms	23
Influence of tedizolid on the cytokine response to the endotoxin challenge in healthy volunteers: a cross-over trial	23
Streptococcus suisprophage lysin as a new strategy for combating streptococci-induced mastitis andStreptococcus suisinfection	23
Pharmacokinetics and placental transfer of dolutegravir in pregnancy	23
Comparison of different biomass methodologies to adjust sales data on veterinary antimicrobials in the USA	23
Absence, loss-of-function, or inhibition of Escherichia coli AcrB does not increase expression of other efflux pump genes supporting the discovery of AcrB inhibitors as antibiotic adjuvants	23

Effect of different strategies for excluding duplicate cultures on the correlation between hospital resistance rates and antibiotic consumption	23
Implementation of the EUCAST rapid antimicrobial susceptibility test (RAST) directly from positive blood culture bottles without the advanced identification systems	23
Safety of topical tobramycin powder during operative treatment of fractures	22
Investigating the cause of increased tetracycline-resistant Neisseria gonorrhoeae in England, 2016–20	22
Effect of sigma E on carbapenem resistance in OXA-48-producing Klebsiella pneumoniae	22
Exploring disparities in HIV-1 pretreatment and acquired drug resistance in China from 2003 to 2022	22
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginos	22
A systematic review of antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium in sub-Saharan Africa	22
Reporting England’s progress towards the ambitions in the UK action plan for antimicrobial resistance: the English surveillance programme for antimicrobial utilisation and resistance (ESPAUR)	22
Rifabutin versus rifampicin bactericidal and antibiofilm activities against clinical strains of Staphylococcus spp. isolated from bone and joint infections	22
Assessment of co-resistance to antibiotics recommended for acute pyelonephritis among Escherichia coli clinical strains from community- and nursing home–acquired urinary tract infections	22
Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia mod	22
Effect of methenamine hippurate shortage on antibiotic prescribing for urinary tract infections in Norway—an interrupted time series analysis	22
Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare	22
Empirical use of β-lactam/β-lactamase inhibitor combinations does not increase mortality compared with cloxacillin and cefazolin in methicillin-susceptible Staphylococcus aureus bacteraemia: a	22
The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections	22
Usefulness of inclusion of ertapenem and temocillin screening breakpoints in the EUCAST rapid antimicrobial susceptibility testing (RAST) for rapid detection of OXA-48-producing Klebsiella pneumoni	21
External quality assurance (EQA) network in South and South-East Asia: experience and results from an international EQA programme in One Health sector reference laboratories	21
Evaluation of fidaxomicin use in patients with a macrolide allergy/intolerance	21
Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales	21
Subcutaneously administered antibiotics: a review (addendum)	21
Characterization of an MDR Lactobacillus salivarius isolate harbouring the phenicol-oxazolidinone-tetracycline resistance gene poxtA	21
Establishment of RCPA national guidelines for selective reporting of antimicrobials: processes, challenges and measuring the impact	21
Population pharmacokinetics of aciclovir and its major metabolite 9-carboxymethoxymethylguanine and safety profile of valaciclovir in early liver transplant recipients	21
Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-	21
Interventions to improve antibiotic use among dentists: a systematic review and meta-analysis	21
Prevalence of drug resistance mutations in low-level viremia patients under antiretroviral therapy in Southwestern China: a cross-sectional study	21
Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis	21
A scoring system to predict resistance to ceftolozane/tazobactam in respiratory isolates of Pseudomonas aeruginosa	21
Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine	21
Comment on: Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes	20
Validation of a modified rapid test to detect the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus from bloodstream infections in hospitals from North and Latin Americ	20
In vitro and in vivo antibacterial activity, resistance analysis and molecular docking study of pleuromutilin derivatives against Streptococcus suis	20
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis	20
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study	19
Diagnostic uncertainties in patients with bacteraemia: impact on antibiotic prescriptions and outcome	19
Swedish multicentre study of target attainments with β-lactams in the ICU: which MIC parameter should be used?	19
Pristinamycin-induced sideroblastic anaemia	19
Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors	19
The acquisition of transferable extrachromosomal fec operon is associated with a cefiderocol MIC increase in Enterobacterales	19
Correction to: Pharmacokinetics of anti-TB drugs in children and adolescents with drug-resistant TB: a multicentre observational study from India	19
The association between bacteriuria and adverse pregnancy outcomes: a systematic review and meta-analysis of observational studies	19
Clinical aspects and recent advances in fungal diseases impacting human health	19
Changes in NNRTI use have not altered the ecology of NNRTI resistance over the last 10 years in people with HIV experiencing virological failure on antiretroviral drugs	19
In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases	19
Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France	19
Population pharmacokinetics of posaconazole in allogeneic haematopoietic stem cell transplant patients	19
Decreased cyclic-AMP caused by ATP contributes to fosfomycin heteroresistance in avian Escherichia coli	18
Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV	18
Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia	18
Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011–2020	18
Influence of ultrafiltration conditions on the measurement of unbound drug concentrations: flucloxacillin as an example	18
Antibiotic use by clinical presentation across all healthcare providers in rural Burkina Faso: a healthcare visit exit survey	18
Temocillin efficacy against AmpC β-lactamase-producing Enterobacterales: a relevant alternative to cefepime?	18
Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates	18
Pharmacokinetic/pharmacodynamic model-based optimization of temocillin dosing strategies for the treatment of systemic infections	18
Impact of veterinary antibiotics on plasmid-encoded antibiotic resistance transfer	18
Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences	18
Stability of temocillin in outpatient parenteral antimicrobial therapy: is it a real option?	18
Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children	18
In vitro activity of fosfomycin against bacterial pathogens isolated from urine specimens in Canada from 2007 to 2020: CANWARD surveillance study	18
Identification of multiple transfer units and novel subtypes of tmexCD-toprJ gene clusters in clinical carbapenem-resistant Enterobacter cloacae and Klebsiella oxytoca	18
Off-label oritavancin treatment outcome and molecular characterization of a vancomycin- and linezolid-resistant Enterococcus faecium causing liver abscesses	18
Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing	18
Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13 694 patients with meta-analysis	18
Population pharmacokinetics of bictegravir in real-world people with HIV	18
Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic	17
A multi-site, international laboratory study to assess the performance of penicillin susceptibility testing of Staphylococcus aureus	17
Genomic surveillance and antimicrobial resistance determinants in Neisseria gonorrhoeae isolates from Uganda, Malawi and South Africa, 2015–20	17
Correction to: In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program	17
Temporal trends in antibiotic prescribing and serious and nonserious infections in children presenting to general practice: a registry-based longitudinal cohort study of 162 507 individuals	17
Clinical, pharmacological, and qualitative characterization of drug–drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa	17
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa	17
Validation of the Antifungal National Antimicrobial Prescribing Survey (AF-NAPS) quality assessment tool	17
GyrB in silico mining in 27 151 global gonococcal genomes from 1928–2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and	17
Surveillance of antimicrobial resistant Shiga toxin-producing E. coli O157:H7 in England, 2016–2020	17
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry	17
Acknowledgement of referees	17
Streptococcal and enterococcal endocarditis: time for individualized antibiotherapy?—authors’ response	17
Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis	16

The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD)	16
In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions	16
Antibiotic prescription patterns during last days of hospitalized patients with advanced cancer: the role of palliative care consultation	16
Co-existence of the oxazolidinone resistance genes cfr and optrA on a novel multiresistance plasmid from a methicillin-resistant Macrococcoides bohemicum strain	16
Impact of changed co-amoxiclav susceptibility testing formats on apparent resistance rates for bloodstream Escherichia coli in a long-term surveillance	16
Diffusion of amoxicillin into heart valves from infective endocarditis patients	16
Preface	16
The antiplasmodial activity of the carboxylic acid metabolite of piperaquine and its pharmacokinetic profiles in healthy volunteers	16
Professor Alasdair Macintosh Geddes, 14 May 1934–9 April 2024	16
In vivo evaluation of cefazolin inoculum effect in the treatment of experimental Staphylococcus aureus pneumonia with cefazolin	16
In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa	16
Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114	16
Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales	16
Raising awareness of antimicrobial resistance: development of an ‘antibiotic footprint calculator’	16
Identification of vancomycin exposure target in neonates: how much is enough?	16
Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients—authors’ response	16
Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphylococcus aureus bacteraemia	16
The pharmacokinetics/pharmacodynamics of ceftazidime/avibactam for central nervous system infections caused by carbapenem-resistant Gram-negatives: a prospective study	16
Carbapenem resistance in Enterobacterales bloodstream infections among children with cancer or post-haematopoietic stem cell transplant: a retrospective cohort study	16
Impact of removing ESBL status labelling from culture reports on the use of carbapenems for non-bacteraemic patients diagnosed with ESBL-positive urinary tract infections	16
A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19	16
Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa	16
In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates	15
Changing epidemiology of MRSA-CC398 in Spanish hospitals located in areas with different pig farming densities: a 2023 multicentre study	15
Broad-spectrum in vitro activity of macrophage infectivity potentiator inhibitors against Gram-negative bacteria and Leishmania major	15
Clinical impact of time to results from the microbiology laboratory in bloodstream infections caused by carbapenemase-producing Enterobacterales (TIME-CPE STUDY)	15
Treatment of persistent focalized Q fever: time has come for an international randomized controlled trial	15
Genomic comparison of mecC-carrying methicillin-resistant Staphylococcus aureus from hedgehogs and humans in the Netherlands	15
Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the	15
Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient	15
Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis?	15
Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments	15
Prevalence and associated factors of antibiotic exposure during pregnancy in a large French population-based study during the 2010–19 period	15
Trends in fluoroquinolone prescribing in UK primary and secondary care between 2019 and 2023	15
Relationship of TonB-dependent receptors with susceptibility to cefiderocol in clinical isolates of Pseudomonas aeruginosa	15
Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up	15
Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach	15
Cefepime–taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018–22	15
Correction to: Linezolid brain penetration in neurointensive care patients	15
In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/	15
In vitro and in vivo evidence discourages routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia species	14
Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa	14
Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial	14
Evaluation of an optimized intermittent vancomycin dosing regimen in infants	14
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting	14
HIV-1 subtype F integrase polymorphisms external to the catalytic core domain contribute to severe loss of replication capacity in context of the integrase inhibitor resistance mutation Q148H	14
Fluoroquinolones in orthopaedic infection: balancing risks and rewards	14
Emergence of mcr-8.1 gene coexisting with blaNDM in Citrobacter werkmanii isolated from a chicken farm in China	14
Activity of rezafungin against Candida auris	14
Gepotidacin: a novel, oral, ‘first-in-class’ triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea	14
Cl415, a carbapenem-resistant Acinetobacter baumannii isolate containing four AbaR4 and a new variant of AbGRI2, represents a novel global clone 2 strain	14
Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study	14
Vancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model	14
Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli isolates	14
Phenotypic and genetic characterization of antimicrobial resistance inSalmonella entericaserovar Choleraesuis isolates from humans and animals in Spain from 2006 to 2021	14
Phenotype–genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt	14
Helicobacter pylori culture positivity and antimicrobial susceptibility profiles (Vancouver, Canada)	14
Do antibiotics cause mitochondrial and immune cell dysfunction? A literature review	14
Foreword	14
Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus	14
Effect of albumin substitution on pharmacokinetics of piperacillin/tazobactam in patients with severe burn injury admitted to the ICU	14
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa	14
Antifungal use in children with acute leukaemia: state of current evidence and directions for future research	14
In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization	14
Comparison of prophylactic antibiotics for endonasal transsphenoidal surgery using a national inpatient database in Japan	14
Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospit	14
Emergence of rare carbapenemases (FRI, GES-5, IMI, SFC and SFH-1) in Enterobacterales isolated from surface waters in Japan	14
Quantitative performance of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin against a challenge set of Klebsiella pneumoniae and Pseudomonas a	14
Oral levofloxacin: population pharmacokinetics model and pharmacodynamics study in bone and joint infections	14
JAC Supplement: ‘faster ID and AST revolution: how to improve antibiotic use in the critically ill’	14
Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23	14
Development and validation of a resazurin assay for in vitro susceptibility testing of Actinomadura madurae: a common causative agent of actinomycetoma	14
Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models	14
Hospitalizations and severe complications following acute sinusitis in general practice: a registry-based cohort study	14
Refractory versus resistant invasive aspergillosis	14
Towards optimizing carbapenem selection in stewardship strategies: a prospective propensity score-matched study of ertapenem versus class 2 carbapenems for empirical treatment of third-generation ceph	14
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy	14
No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors	13
Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model againstKlebsiella pneumoniae—authors’ response	13
Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics	13
Isavuconazole–tacrolimus drug–drug interactions in HSCT patients	13
Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes	13
Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America	13
Disulfiram enhances meropenem activity against NDM- and IMP-producing carbapenem-resistantAcinetobacter baumanniiinfections	13
Correction to: Up-regulation of silent information regulator 2 (Sir2) is associated with amphotericin B resistance in clinical isolates of Leishmania donovani	13
High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study	13
Depolymerase as a potent adjunct to polymyxin for targeting KL160 pandrug-resistant Acinetobacter baumannii in a murine bacteremia model	13
Country data on AMR in Mexico in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, acc	13
Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis	13
Rapid detection of CTX-M-type ESBLs and carbapenemases directly from biological samples using the BL-DetecTool	13
Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19)—authors’ response	13
Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France	13
Synergistic bactericidal activity of a novel dual β-lactam combination against methicillin-resistant Staphylococcus aureus	13
Correction to: Plasmid-mediated azithromycin resistance in non-typhoidal Salmonella recovered from human infections	13
Rapid determination of ceftazidime/avibactam susceptibility of carbapenemase-producing Enterobacterales directly from blood cultures: a comparative evaluation of EUCAST disc diffusion RAST and direct	13